Revealed, listed below are the latest additions to Zacks Rank #1 (Strong Buy) List:
Skyward Specialty Insurance Group, Inc. SKWD: A robust contender in the insurance sector, specializing in underwriting commercial property and casualty insurance primarily in the United States. This company has experienced a remarkable surge in its Zacks Consensus Estimate for current-year earnings, escalating by a notable 6.7% over the past 60 days.
Performance Review of Skyward Specialty Insurance Group, Inc.
Skyward Specialty Insurance Group, Inc. price-consensus-chart | Skyward Specialty Insurance Group, Inc. Quote
Koninklijke Philips PHG: This technology giant specializing in health diagnostics & treatment businesses, connected care businesses, and personal health businesses segments has seen a solid 4.7% increase in the Zacks Consensus Estimate for its current-year earnings over the past 60 days.
Koninklijke Philips N.V. Performance Review
Koninklijke Philips N.V. price-consensus-chart | Koninklijke Philips N.V. Quote
The Bank of New York Mellon BK: A prominent player in the financial services arena, operating across 35 countries and offering an array of products and services to individuals and institutions. The company has witnessed a 2.2% surge in the Zacks Consensus Estimate for its current-year earnings in the last 60 days.
The Bank of New York Mellon Corporation Performance Review
The Bank of New York Mellon Corporation price-consensus-chart | The Bank of New York Mellon Corporation Quote
PagSeguro Digital PAGS: A global player providing financial technology solutions and services catering to micro-merchants and small and medium-sized businesses, primarily in Brazil and on an international scale. The company has observed a 2.0% uptick in the Zacks Consensus Estimate for its current-year earnings over the previous 60 days.
PagSeguro Digital Ltd. Performance Review
PagSeguro Digital Ltd. price-consensus-chart | PagSeguro Digital Ltd. Quote
Genmab GMAB: A leading biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company has witnessed a 1.7% increase in the Zacks Consensus Estimate for its current-year earnings over the last 60 days.
Genmab A/S Sponsored ADR Performance Review
Genmab A/S Sponsored ADR price-consensus-chart | Genmab A/S Sponsored ADR Quote
Keep a lookout for the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Only $1 to See All Zacks’ Buys and Sells
Surprising but true. A few years back, Zacks astonished many by offering a 30-day privilege of accessing all their picks for a negligible sum of $1. No obligations beyond that. Thousands have embraced this opportunity, while thousands remained skeptical, unable to believe such a deal existed without a catch. The motivation behind this offering is to introduce investors to Zacks’ portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, which have already closed a remarkable 162 positions with double- and triple-digit gains in 2023 alone.